Viamet is a clinical-stage infectious disease company that discovers and develops novel, small molecule therapies for the treatment of human fungal infections. Using our proprietary Metallophile® Technology, we have built a portfolio of novel antifungal compounds which address significant unmet medical needs and represent blockbuster commercial potential. VT-1161 is an oral, small molecule inhibitor in Phase 2 clinical development for the treatment of onychomycosis and recurrent vulvovaginal candidiasis. VT-1129 is a late-stage, pre-clinical molecule for the oral treatment of cryptococcal meningitis, a serious and life-threatening fungal infection. VT-1598 is a pre-clinical compound for the IV and oral treatment of life-threatening fungal infections such as invasive candidiasis and aspergillosis.